Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces Increased Revenues for 2001 Third Quarter and Nine Months Results
Arena Pharmaceuticals Announces Increased Revenues for 2001 Third Quarter and Nine Months Results SAN DIEGO, Oct. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.5 million for the quarter ended September 30, 2001, a 50% increase over third quarter 2000
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For Third Quarter Earnings Conference Call Thursday, October 18, 2001 Live at 4:30 p.m. Eastern Time
Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For Third Quarter Earnings Conference Call Thursday, October 18, 2001 Live at 4:30 p.m. Eastern Time SAN DIEGO, Oct 2, 2001 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access to Review 2001 Guidance During a Wednesday September 5, 2001 Conference Call, Live at 4:15 P.M. Eastern Time
Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access to Review 2001 Guidance During a Wednesday September 5, 2001 Conference Call, Live at 4:15 P.M. Eastern Time SAN DIEGO, Aug 31, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Multi-Receptor CART Collaboration With TaiGen Biotechnology Co., Ltd.
Arena Pharmaceuticals, Inc. Announces Multi-Receptor CART Collaboration With TaiGen Biotechnology Co., Ltd. SAN DIEGO, Aug 20, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA); ("Arena") today announced the signing of a license agreement with TaiGen Biotechnology Co., Ltd.
View HTML
Toggle Summary Arena Pharmaceuticals Announces 2001 Second Quarter and Six Months Results and Reaffirms Financial Guidance for 2001
Arena Pharmaceuticals Announces 2001 Second Quarter and Six Months Results and Reaffirms Financial Guidance for 2001 SAN DIEGO, Jul 23, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.3 million for the quarter ended June 30, 2001, a 158% increase over
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Olfactory Receptor Agreement With ICI
Arena Pharmaceuticals, Inc. Announces Olfactory Receptor Agreement With ICI SAN DIEGO, July 9 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with the ICI group to apply Arena's proprietary CART technology to olfactory and gustatory G
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For Second Quarter Earnings Conference Call Monday July 23, 2001 Live At 4:30 P.M. Eastern Time
Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For Second Quarter Earnings Conference Call Monday July 23, 2001 Live At 4:30 P.M. Eastern Time SAN DIEGO, Jul 5, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option
Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option SAN DIEGO, Jul 2, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriting group managed by Thomas Weisel Partners LLC, Dain Rauscher Wessels, ABN AMRO Rothschild LLC and Lazard
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Follow-on Offering Of 5,000,000 Shares of Common Stock
Arena Pharmaceuticals, Inc. Announces Follow-on Offering Of 5,000,000 Shares of Common Stock SAN DIEGO, June 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its follow-on offering of 5,000,000 shares of its common stock was priced on June 21, 2001 at $27.50 per
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces a Follow-On Offering of Common Stock
Arena Pharmaceuticals, Inc. Announces a Follow-On Offering of Common Stock SAN DIEGO, June 5 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed follow-on offering of
View HTML